A comparison of effect of dexmedetomidine according to body composition

A comparison of pharmacologic effect of dexmedetomidine according to body composition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005737

Enrollment

280

Registered

2021-01-05

Start date

2021-01-18

Completion date

Unknown

Last updated

2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Intravenous dexmedetomidine is administered following successful regional block. Dexmedetomidine is generally infused with loading dose of 1ug/kg and, followed with continous infusion of 0.2-1.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • 18-75 years, ASA/PS I or II, patients who were scheduled to undergo upper of lower extremity surgery under regional anesthesia • patients with informed consent

Exclusion criteria

Exclusion criteria: 1. patient refusal 2. severe hepatorenal impairment 3. difficulty of communication such as hearing impairment 4. metal implant due to previous surgery 5. cardiac pacemaker of ICD

Design outcomes

Primary

Measure	Time frame
Required dose of dexmedotomidine for LOC µg)	—

Secondary

Measure	Time frame
time to LOC, sedation level at LOC, BIS at LOC, time to BIS 80 and 90, vital signs	—

Countries

Korea, Republic of

Contacts

Public ContactA Ram Doo

Jeonbuk National University

Outcome results